MSFrontier

Evaluation of the Efficacy of Cesamet™ for the Treatment of Pain in Patients With Multiple Sclerosis

A Multicenter Trial Evaluating the Efficacy of Cesamet™ for the Symptomatic Treatment of Pain in Patients With Multiple Sclerosis
CompletedPhase 4MS (type not specified)NCT00381264

What it found

No result found

We found no results in the registry or in papers.

This trial finished 19 years ago. We found no results in the registry or in any paper that cites it.

What was tested

Treatment tested

  • Nabilone

    Cannabinoid CB1 receptor agonist

What it measured

Main measures

  • The Average Pain Score at target site.

    Pain

Other measures (5)

  • The Worst Pain Score at target site.

    Pain

  • The Pain at Night Score at target site.

    Pain

  • Quality of Life measures.

    Quality of life (reported by participants)

  • Patient satisfaction with treatment.

    Quality of life (reported by participants)

  • Safety will be assessed through the collection of AEs and vital signs.

    Safety

Who could take part

MS (type not specified) · 18 to 75

Inclusion Criteria: * Patients diagnosed with MS * Chronic daily pain present for at least 2 months. * On stable analgesic regimen for one month * Baseline pain score greater than 40mm on a visual analog scale. Exclusion Criteria: * Hypersensitivity to compounds in study drug or similar drugs * Pregnant or lactating females * Drug or alcohol abuse * Unstable medical condition

As registered. Criteria can change, so ask the trial team or your neurologist.

About this trial

In the sponsor's words

This study was designed to evaluate the safety and efficacy of Cesamet™ in controlling pain in subjects experiencing pain due to Multiple Sclerosis.

Loading reviews and guidelines…

Related trials

History

    1. Started

      Sept 2006

    2. Main results due

      Oct 2007

    3. Finished

      Oct 2007

    Assembled by software from public sources and not checked by people. Each record links to its source. Report an error